Increased CMV disease and "severe" BK viremia with belatacept vs. sirolimus three-drug maintenance immunosuppression.

Gregory PetrossianJorge OrtizAlejandro Chiodo OrtizKathryn AddonizioAlexander HsiaoRosy JamesNaoru KoizumiSunil PatelRobert Plews

Published in: Transplant immunology (2023)

Belatacept therapy was associated with an increased risk of CMV disease and "severe" CMV and BK viremia. However, this regimen did not increase the overall incidence of infection and facilitated comparable acute rejection and graft loss at 12-month follow up.

Keyphrases

drug induced
early onset
liver failure
risk factors
respiratory failure
emergency department
extracorporeal membrane oxygenation
intensive care unit
acute respiratory distress syndrome
cell therapy
replacement therapy